[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster III

Program: Oral and Poster Abstracts
Type: Poster
Monday, December 12, 2011: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Secondary Primary Malignancies in Patients with Multiple Myeloma Treated with High-Dose Chemotherapy and Autologous Blood Stem Cell Transplantation

Roland Fenk, MD1*, Florian Neubauer1*, Ingmar Bruns, MD2, Christian Saure, MD3*, Thomas Schroeder, MD4*, Ulrich Germing, MD5*, Norbert Gattermann, MD6, Rainer Haas, MD, Prof1* and Guido Kobbe, MD7*

1Hematology, Oncology, Heinrich Heine University, Duesseldorf, Germany
2Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany
3Hematology, Oncology and Clinical Immunology, University of Duesseldorf, 40225 Duesseldorf, Germany
4Hematology, Oncology and Clinical Immunology, Heinrich Heine University Duesseldorf, University Hospital, Duesseldorf, Germany
5Hematology, University Hospital Düsseldorf, Düsseldorf, Germany
6Heinrich-Heine-Universitat, Düsseldorf, Germany
7Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University of Düsseldorf, Duesseldorf, Germany

Correlation Between Severity of cGvHD and Transplant Outcome: A Retrospective Monocenter Study Based on NIH Classification

Colombe Saillard1*, Roberto Crocchiolo, MD2*, Sabine Furst, MD3*, Jean El-Cheikh, MD PhD4*, Luca Castagna, MD5*, Claire Oudin6*, Catherine Faucher, MD6*, Lemarie Claude7*, Christian Chabannon, MD, PhD8, Angela Granata6* and Didier Blaise, MD9

1Institut Paoli-Calmettes, Marseille , France
2Institut Paoli Calmettes , Marseille, France
3Institut Paoli-Calmettes, marseille , France
4Institut Paoli Calmettes, Marseille
6Institut Paoli-Calmettes, Marseille, France
7Institut Paoli-Calmettes, marseille, France
8Institut Paoli Calmettes, Marseille, France
9Hematology, Institut Paoli-Calmettes, Marseille, France

Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Severe Alpastic Anemia After Cyclophosphamide Plus Antithymocyte Globulin Conditioning Regimen

Johanna Konopacki, MD1*, Raphael Porcher2*, Marie Robin3*, Sabine Bieri4*, Jean Michel Cayuela, MD, PhD5*, Jérome Larghero6*, Alienor Xhaard7*, Anna-Lisa Andreoli, MD8*, Nathalie Dhedin, MD9*, Anna D. Petropoulou, MD10, Paula Rodriguez-Otero, MD, PhD9*, Patricia Ribaud7, Helene Moins, MD, PhD11*, Mariyvonnick Carmagnat11*, Antoine Toubert, MD, PhD12*, Yves Chalandon, MD13, Gérard Socié7 and Régis Peffault de Latour14*

1Hématologie Greffe, Hôpital Saint Louis, Paris, France
2Biostatistics, Saint-Louis Hospital, Paris, France
3Hematologie Greffe, Hôpital Saint-Louis, APHP, Paris, France
4Hematologie, Hopital Universitaire de Geneve, geneve, Switzerland
5Institut Universitaire d'Hématologie, Université Paris 7, Hôpital Saint Louis, Paris, France
6Cell Biology Unit, Hopital Saint-Louis, Paris, France
7Hematology-Bone Marrow Transplantation, Saint-Louis Hospital, Paris, France
8Hematology, Hôpital Saint Louis, Paris, France
9Hématologie Greffe, Hopital Saint Louis, Paris, France
10Hematology-Bone Marrow Transplantation, Saint-Louis Hospital, 75010 Paris, France
11Laboratoire d'Immunologie et d'histocompatibilité, Hôpital Saint Louis, Paris, France
12Departement d'Immunologie, Université Paris Diderot, INSERM UMRS-940, AP-HP, Paris, France
13Division of Hematology, Univ. Hospital of Geneva, Geneva, Switzerland
14Hematologie Greffe, Hopital Saint-Louis, Paris, France

CD34 Expression in Adult Acute Lymphoblastic Leukemia (ALL) Is a Favorable Prognostic Factor in Patients Treated with Stem Cell Transplant in First Remission

Mahmoud Aljurf, M.D.1, Naeem A. Chaudhri, MD, FACP1, Fahed Almhareb, MBBS, FACP1, Claudia Ulrike Walter, PhD2*, Randa Nounou, M.D.2*, Salem Khalil, M.D.2*, Nasir Bakshi, M.D.2, Tarek Owaidah, MD, FRCPA2, Hazzaa Al Zahrani, M.D.1*, Said Mohamed, M.D.1*, Walid Rasheed, M.D.1*, Fahad Alsharif, M.D.1 and Maher Albitar, M.D.2

1Oncology Center , King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
2Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

CD11b Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation

Maher Albitar, M.D.1, Amal Alseraihy, M.D.2*, Mouhab Ayas2*, Abdullah Al-Jefri, M.D.2*, Ali Al-Ahmari, MD2*, Asim F Belgaumi, MD2, Claudia Ulrike Walter, PhD1*, Randa Nounou, M.D.1*, Salem Khalil, M.D.1*, Nasir Bakshi, M.D.1, Tarek Owaidah, MD, FRCPA1 and Hassan El-Solh, MD2*

1Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
2Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management

Mauricette Michallet1, Mohamad Sobh, Pharm.M.1*, Stephane Morisset, Stat.1*, Helene Labussiere, MD1*, Marie Y. Detrait, MD1, Sophie Ducastelle, MD1*, Fiorenza Barraco, MD1*, Jihane Fattoum, MD, PhD1*, Nathalie Tedone, CRA1*, Youcef Chelghoum, MD1*, Giovanna Cannas, MD1*, Xavier Thomas, MD, PhD1* and Franck E. Nicolini, MD, PhD2

1Hematology, Hopital Edouard Herriot, HCL, Universite Lyon 1, Lyon, France
2Hopital Edouard Herriot, Lyon, France

Upfront Tandem Autologous Stem Cell Transplant Is Superior to Autologous or Allogeneic Stem Cell Transplant After Failure of a 1st Autologous Transplant

Adrian Wong, MD1*, Charles F. LeMaistre, MD2, Paul Shaughnessy, MD2 and Carlos Bachier, MD2

1Adult Blood and Marrow Transplantation, Texas Transplant Institute, San Antonio, TX
2Texas Transplant Institute, San Antonio, TX

Nelarabine-Based Salvage Therapy in Adult Patients with T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (T-ALL/LL) Relapsing After Allogeneic Stem Cell Transplantation: A French Experience on Behalf of the Group for Research in Adult Lymphoblastic Leukemia (GRAAL)

Edouard Forcade, MD1*, Thibaut Leguay, MD2*, Norbert Vey, MD3*, Andre Baruchel4*, Jacques Delaunay5*, Marie Robin6*, Gérard Socié7, Hervé Dombret8*, Emmanuel Raffoux, MD, PhD9* and Régis Peffault de Latour10*

1Hematologie Greffe, Hôpital Saint Louis, Paris, France
2Hôpital Haut-Lévêque, Université Bordeaux, Pessac, France
3Institut Paoli Calmettes, Université Marseille, Marseille, France
4Dept. of Pediatric Hematology, Hopital Robert Debre, Paris, France
5CHU Nantes, Université Nantes, Nantes, France
6Hematologie Greffe, Hôpital Saint-Louis, APHP, Paris, France
7Hematology-Bone Marrow Transplantation, Saint-Louis Hospital, Paris, France
8Hôpital Saint-Louis, AP-HP, Université Paris 7, Paris, France
9Hôpital Saint-Louis APHP University Paris VII, Paris, France
10Hematologie Greffe, Hopital Saint-Louis, Paris, France

Long-Term Survival and Quality of Life Assessment After Allogeneic Stem-Cell Transplantation; Comparable Results Following Myeloablative and Reduced-Intensity Conditioning

Avichai Shimoni, MD1*, Eran Tallis, MD1*, Noga Shem-Tov, MD1*, Yulia Volchek, MD1*, Ronit Yerushalmi, MD1 and Arnon Nagler2

1Hematology Division and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
2Hematology Division, Chaim Sheba Medical Center and Tel Aviv University, Guy Weinshtock Multiple Myeloma Foundation, Tel-Hashomer, Israel

High Throughput Screening for Antibody Responses Against H-Y Antigens and Their X-Variants in Allogeneic Hematopoeietic Stem Cell Transplantation

Judith C van der Griendt, MSc1*, Edith D van der Meijden1*, Burcu Ayoglu2*, Jochen M Schwenk2*, Peter Nilsson2*, J.H. Frederik Falkenburg, MD, PhD1 and Marieke Griffioen, PhD1*

1Department of Hematology, Leiden University Medical Center, Leiden, Netherlands
2Department of Proteomics, School of Biotechnology, Royal Institute of Technology (KTH) , Stockholm, Sweden

CXCR4 allelic Variations Influence Hematological Recovery Following Autologous Stem Cell Transplantation

María L. Lozano1,2*, Elkin A. Niño1,2*, Juan Jose Cerezo1,2*, Cristina Castilla-Llorente1,2*, Ana I. Anton2*, Jose Padilla2*, Inmaculada Heras1,2* and Vicente Garcia1,2

1Hematology and Clinical Oncology Unit, Hospital General Universitario Morales Meseguer, Murcia, Spain
2Universidad de Murcia, Centro Regional de Hemodonacion, Murcia, Spain

Chronic Graft Versus Host Disease (GVHD) Does Not Impact Cardiovascular Risk Factors in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) up to the Second Decade Post-Transplant

Priyanka A Pophali, MD1*, Kamna Chawla, MD, MS2*, Eleftheria K. Koklanaris, BSN2*, Avan Antia1*, Simar Chawla1*, Sawa Ito, MD2, Jeffrey K. Klotz, MD1, Robert Q. Le, MD, PhD2, A. John Barrett, MD, FRCP3 and Minoo Battiwalla, MD, MS2

1Hematology, NHLBI, Bethesda, MD
2Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
3NHLBI, NIH, Bethesda, MD

Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT)

Aline Clavert, MD1*, Peric Zina, MD2*, Xavier Cahu, MD3*, Patrice Chevallier, MD4*, Eolia Brissot5*, Florent Malard5*, Thierry Guillaume6*, Jacques Delaunay, MD7*, Sameh Ayari5*, Viviane Dubruille5*, Beatrice Mahe5*, Nicolas Blin, MD8*, Thomas Gastinne9*, Virginie Roland10*, Steven Le Gouill, MD, PhD10*, Jean-Luc Harousseau2,11, Philippe Moreau, MD12*, Noel Milpied, MD13 and Mohamad Mohty14

1Hematology, centre hospitalo-universitaire, Nantes, France
2Hematologie, Centre Hospitalo-Universitaire, Nantes, France
3Hematologie, Centre Hospitalo-Universitaire, Rennes, France
4Hematology, Centre Hospitalo-Universitaire, Nantes, France
5Hematology Department, CHU de Nantes, Nantes, France
6Service d'Hématologie Clinique, CHU, Nantes, France
7Hopital Hotel Dieu, Nantes, France
8Hematology, CHU de Nantes, Nantes, France
9Service D'hématologie Clinique, CHU de Nantes, Nantes, France
10Service d'hématologie clinique, Centre hospitalier universitaire de Nantes, Nantes, France
11Oncologie, CRLCC, Saint Herblain, France
12Hematology Department, University Hospital of Nantes, Nantes , France
13Hematology, CHU Bordeaux, Pessac, France
14Hematology department, CHU de Nantes, Nantes, France

Outcome of Children Who Experience Disease Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies

Rajinder PS Bajwa, MBBS, MD, MRCP1, Sandeep Soni, MBBS1, Tal Schechter, MD2*, Adam Gassas, MD2, John J Doyle, MD2, India Sisler, MD3, Kamar Godder, MD, MPH3, David Tatman, BA4*, Stephen Rumelhart, MD4*, Jennifer Domm, MD5 and Haydar Frangoul, MD5

1Department of Hematology Oncology and BMT, Nationwide Children's Hospital, Columbus, OH
2University of Toronto Dept. of Hem./Onc./BMT, The Hospital for Sick Children, Toronto, ON, Canada
3Pediatric Hematology/Oncology, Virginia Commonwealth University, Richmond, VA
4Department of Pediatrics Hem/Onc, University of Iowa Hospitals and Clinics, Iowa City, IA
5Pediatric Hem./Onc., Vanderbilt Univ. Medical Ctr., Nashville, TN

Monitoring of Wilms’ Tumor Gene 1 Levels Predict Early Relapse After Allogeneic Hematopoietic Stem Cells Transplantation in Patients with High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Elisa Sala, MD1*, Carlo Messina, MD2*, Cristina Tresoldi2*, Matteo Carrabba, MD2*, Michela Tassara, MD2*, Alessandro Crotta, MD2*, Alessandro Vignati2*, Elena Guggiari, MD2*, Roberta Mattarucchi2*, Andrea Assanelli, MD2*, Jacopo Peccatori, MD2*, Consuelo Corti, MD2*, Fabio Ciceri, MD2* and Massimo Bernardi, MD3*

1Haematology and Bone Marrow Transplantation Unit - EBMT cic 813, San Raffaele Scientific Institute, Milan, Italy
2Haematology and BMT Unit, San Raffaele Scientific Instute, Milan, Italy
3Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy

The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission

Andrew J Innes, MBChB1*, James Lurkins1*, Richard M Szydlo1*, Andrea Guerra1*, Dragana Milojkovic, MD1*, Jiri Pavlu1*, Edward J Kanfer1*, David Marin1, Donald MacDonald1*, Amin Rahemtulla1, Sandra Loaiza2*, Stephanie Kirschke2*, Katayoun Rezvani, MD, PhD1, John Goldman1*, Jane F Apperley, MBChB, MD, FRCP, FRCPath1 and Francesco Dazzi1*

1Department of Haematology, Imperial College, London, United Kingdom
2Department of Haematology, Imperial College NHS Trust, London, United Kingdom

Massively Parallel Immunoglobulin Gene Sequencing Provides Ultra-Sensitive Minimal Residual Disease Detection and Predicts Post-Transplant Relapse in Acute Lymphoblastic Leukemia by Three to Six Months

Aaron C. Logan, MD, PhD1, Nikita Vashi, BS1*, Malek Faham, MD, PhD2*, Victoria Carlton, PhD2*, Ismael Buno, MD3*, Jianbiao Zheng, PhD2*, Martin Moorhead, PhD2*, Mark Klinger, PhD2*, Tom Willis, PhD2*, Melody B. Zhang, PhD4*, Amna Waqar4*, James L. Zehnder, MD4* and David B. Miklos, MD, PhD1

1Dept. of Medicine, Div. of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA
2Sequenta, Inc., South San Francisco, CA
3Dept. of Hematology, Hospital G.U. Gregorio Maranon, Madrid, Spain
4Dept. of Pathology, Stanford University School of Medicine, Stanford, CA

Gonadal Function In Patients with Beta-Thalassemia Major Following Bone Marrow Transplantation

Khalil Al Farsi, BSc MD ABIM FRCPC1, Murtadha K. Al-Khabori, MD, FRCPC2, Fehmida Zia, MBBS1*, Moez Abdul-Rahim, MBBS3*, Yusra Al-Habsi, BSc4*, Eman Al-Manthari, BSc5*, J. David Dennison, MD3 and Shahina Daar, MD, PhD6*

1Hematology, Sultan Qaboos University Hospital, Al-Khod, Oman
2 Hematology, Sultan Qaboos University, Muscat, Oman
3Hematology, Sultan Qaboos University Hospital, AL-Khod, Oman
4Department of Nursing, Sultan Qaboos University Hospital, Al-Khod, Oman
5Department of Nursing, Sultan Qaboos Univeristy Hospital, Al-Khod
6Hematology, Sultan Qaboos University, Muscat, Oman

*signifies non-member of ASH